Press Releases

$200 million upfront payment received in December 2022 from CSL collaboration Achieved $90 million in development milestones in March 2023 under CSL collaboration ARCT-154 Phase 3 COVID-19 booster trial enrollment completed in Japan Multiple patients enrolled in ARCT-810 Phase 2 multiple ascending

Arcturus to present at the Guggenheim Healthcare Talks: Genomic Medicines & Rare Disease Day, April 3, 2023 SAN DIEGO --(BUSINESS WIRE)--Mar. 7, 2023-- Arcturus Therapeutics Holdings Inc. (the “Company,” “Arcturus,” Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused

SAN DIEGO --(BUSINESS WIRE)--Feb. 6, 2023-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and

SAN DIEGO --(BUSINESS WIRE)--Jan. 31, 2023-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, “Arcturus Therapeutics”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities

SAN DIEGO --(BUSINESS WIRE)--Dec. 19, 2022-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and

Dr. Markels , accomplished and experienced industry executive, most recently President of Global Vaccines at Merck, to provide strategic oversight to the Company’s vaccine franchise SAN DIEGO --(BUSINESS WIRE)--Dec. 13, 2022-- Arcturus Therapeutics Holdings Inc.

CSL to access late-stage next-generation mRNA platform technology, enabling development of vaccines for COVID-19, influenza, multi-pathogen pandemic preparedness and other respiratory pathogens KING OF PRUSSIA, Pa. , Dec. 12, 2022 /PRNewswire/ -- CSL Limited (ASX:CSL; USOTC:CSLLY) today announced

Entered into global partnership with CSL to develop and commercialize self-amplifying mRNA vaccines targeting COVID-19, influenza, additional pathogens, and pandemic preparedness with $200 million upfront and up to $4.3 billion in potential development and commercial milestones BARDA award

SAN DIEGO --(BUSINESS WIRE)--Nov. 7, 2022-- Arcturus Therapeutics Holdings Inc. (the “Company,” “Arcturus,” Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and

Arcturus to receive upfront payment of $200 million and more than $4 billion in potential development and commercial milestones 40% profit sharing for COVID-19 vaccines, up to double digit royalties for influenza, pandemic preparedness and three additional respiratory infectious disease vaccines